Skeena Resources (NYSE:SKE) Shares Gap Up - Time to Buy?

Skeena Resources (NYSE:SKE) saw its shares gap up at market open to $25.80 from a $24.44 close, trading around $24.90 intraday, representing a 2.2% move. Analyst sentiment is mixed but generally positive, with an average "Moderate Buy" rating from MarketBeat based on one Strong Buy, four Buy, and one Sell rating. The company has a market cap of $3.02 billion and a negative P/E, having recently missed EPS estimates, with analysts forecasting negative EPS for the current fiscal year.

Original reporting
MarketBeat · MarketBeat
Published Dec 15, 2025, 5:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Dec 15, 2025, 6:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Skeena Resources (NYSE:SKE) Shares Gap Up - Time to Buy? — source image
Decision brief

The 30-second read

$SKENeutralMed
01

Why it matters

The gap up suggests short-term bullishness possibly driven by technical factors or speculative trading, but underlying fundamentals warrant caution.

02

Market read

While the stock's recent movement is notable, fundamental concerns limit long-term optimism; short-term trading opportunities exist.

03

What to watch

Potential for profit-taking after the initial gap, and broader market volatility could impact the stock's trajectory.

Relevance 6/10Timing: Immediate; the gap up occurred at market open today.

Background

Skeena Resources is a mining company with recent earnings miss, leading to mixed investor sentiment.

Company-level read

Ticker impact

$SKENeutralMedium confidence
Context

Primary focus of the news due to significant price movement and recent earnings performance.

Expected impact

Moderate short-term upward movement (~3-5%), with potential for volatility due to earnings concerns.

Evidence & confidence

The gap up and positive analyst ratings support short-term bullishness; however, recent earnings miss and negative P/E introduce caution.

Market effects

Potential positive sentiment in mining and exploration sectors due to Skeena's price movement.

Limited; primarily affecting US and Canadian markets where Skeena is listed.

Low; company-specific news with limited global implications.

Counterpoint

The recent gap up may be a short-term spike driven by technical factors; fundamentals remain weak due to earnings miss.

Key entities

  • Skeena Resources

    A mining company listed on NYSE with a focus on exploration and development.

Related articles

Med

UBS Gives a Buy Rating to Skeena Resources (SKE)

UBS analyst Daniel Major assigned a Buy rating to Skeena Resources (SKE) with a C$60.00 price target. The average analyst consensus is Moderate Buy with a C$56.00 target. Skeena reported a Q2 GAAP net loss of C$35.22 million, slightly improved from last year's C$36.03 million loss. Insider sentiment is negative, with increased selling activity.

$NEMMed

Ottawa’s $500M Red Chris bet tests BC grid

Ottawa will contribute C$500M (US$352M) to Newmont’s proposed Red Chris Block Cave, linking mine funding to British Columbia’s North Coast Transmission Line. The deal also includes C$3.9B for BC Hydro’s first two stages. Red Chris needs up to 145 MW; the expansion could add ~14 years of mine life and ~1,800 construction jobs, according to Newmont.

$NEMMedAI 8/10

British Columbia critical minerals push faces delivery test: PwC

A PwC Canada report says British Columbia and Yukon could lose ground in critical minerals supply unless they speed mine construction, power buildout and permitting. PwC’s BC Mine 2025 notes metallurgical coal fell to <50% of BC mining revenue in 2024 from >60% in 2023, while copper rose to 25% from 19%. It cites demand driven by industrial policy and energy security, and highlights infrastructure constraints.

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$SHAZMed

What SharonAI (SHAZ) Said on Its Q3 Earnings Call

SharonAI (SHAZ) reported Q3 earnings, highlighting a $1.32B agreement and new contracts totaling $1.17B. The company terminated a $373M contract due to credit risk. CFO Anuj Goel noted $2.6B in capital secured since December 2025, with $1.3B in cash as of Sept. 30. The NVIDIA AICP program covers 72MW and 40,000 GPUs, with billing expected from Q3 2027. SharonAI plans to fund build-out with secured debt and expects $800M in customer deposits.